BioNTech (UK) Today
| 0A3M Stock | USD 118.55 0.15 0.13% |
Performance10 of 100
| Odds Of DistressLess than 9
|
BioNTech is selling for 118.55 as of the 2nd of December 2024. This is a 0.13 percent increase since the beginning of the trading day. The stock's lowest day price was 113.89. BioNTech has less than a 9 % chance of experiencing financial distress in the next few years and had a ok performance during the last 90 days. Equity ratings for BioNTech SE are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 13th of December 2022 and ending today, the 2nd of December 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | Category Healthcare | Classification Health Care |
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany. BIONTECH operates under Biotechnology classification in Japan and is traded on IOB. The company has 239.77 M outstanding shares. More on BioNTech SE
Moving against BioNTech Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
BioNTech Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. BioNTech's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding BioNTech or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | ||||
BioNTech's financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to BioNTech's success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | |||||
BioNTech can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand BioNTech's financial leverage. It provides some insight into what part of BioNTech's total assets is financed by creditors.
| |||||
BioNTech SE (0A3M) is traded on London IL in UK and employs 5,500 people. BioNTech is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Large-Cap' category with a current market capitalization of 32.57 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate BioNTech's market, we take the total number of its shares issued and multiply it by BioNTech's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. BioNTech SE operates under Biotechnology sector and is part of Health Care industry. The entity has 239.77 M outstanding shares.
BioNTech SE has accumulated about 914.9 M in cash with 5.37 B of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.75.
Check BioNTech Probability Of Bankruptcy
Ownership AllocationBioNTech holds a total of 239.77 Million outstanding shares. BioNTech SE shows majority of its outstanding shares owned by insiders. An insider is usually defined as a corporate executive, director, member of the board or institutional investor who own at least 10% of the company's outstanding shares. 65.11 percent of BioNTech SE outstanding shares that are owned by insiders signifies that they have been buying or selling the stock in recent months in anticipation of some upcoming event. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check BioNTech Ownership Details
BioNTech SE Risk Profiles
Although BioNTech's alpha and beta are two of the key measurements used to evaluate BioNTech's performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 2.43 | |||
| Semi Deviation | 2.69 | |||
| Standard Deviation | 3.97 | |||
| Variance | 15.79 |
BioNTech Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in BioNTech without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Price Exposure Probability Now
Price Exposure ProbabilityAnalyze equity upside and downside potential for a given time horizon across multiple markets |
| All Next | Launch Module |
BioNTech Corporate Management
Elected by the shareholders, the BioNTech's board of directors comprises two types of representatives: BioNTech inside directors who are chosen from within the company, and outside directors, selected externally and held independent of BioNTech. The board's role is to monitor BioNTech's management team and ensure that shareholders' interests are well served. BioNTech's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, BioNTech's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Oliver Hennig | VP Operations | Profile | |
| Jens Holstein | CFO Board | Profile | |
| Sylke Maas | VP Strategy | Profile | |
| James Ryan | Chief Board | Profile | |
| Michael Boehler | MD Communications | Profile | |
| Ryan Richardson | MD Officer | Profile | |
| Sierk Poetting | COO MD | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioNTech SE. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.